Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Synergy Pharma (SGYP)

Synergy Pharma (SGYP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Synergy Pharma 420 LEXINGTON AVENUE SUITE 2012 NEW YORK NY 10170 USA

www.synergypharma.com P: 212-297-0020

Description:

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.

Key Statistics

Overview:

Market Capitalization, $K 7,441
Shares Outstanding, K 248,037
Annual Sales, $ 16,820 K
Annual Net Income, $ -224,340 K
Last Quarter Sales, $ 11,110 K
Last Quarter Net Income, $ -34,540 K
60-Month Beta 4.94
% of Insider Shareholders 4.80%
% of Institutional Shareholders 28.47%
Float, K 236,131
% Float 95.20%

Growth:

1-Year Return -98.65%
3-Year Return -99.16%
5-Year Return -99.50%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -72.88%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.15 on 05/10/18
Latest Earnings Date 03/07/19
Earnings Per Share ttm -0.59
EPS Growth vs. Prev Qtr -16.67%
EPS Growth vs. Prev Year 36.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-2 on 12/01/11

SGYP Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -118.14%
Profit Margin % -1,333.77%
Debt/Equity N/A
Price/Sales 0.18
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.39
Interest Coverage -41.57
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar